Cargando…
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
PURPOSE: To establish minimal important differences (MIDs) for the European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with metastatic breast cancer. METHODS: The dataset was obtained from the SELECT BC-CONFIRM randomized clin...
Autores principales: | Kawahara, Takuya, Taira, Naruto, Shiroiwa, Takeru, Hagiwara, Yasuhiro, Fukuda, Takashi, Uemura, Yukari, Mukai, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098551/ https://www.ncbi.nlm.nih.gov/pubmed/34982354 http://dx.doi.org/10.1007/s11136-021-03074-y |
Ejemplares similares
-
Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
por: Hagiwara, Yasuhiro, et al.
Publicado: (2020) -
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017) -
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials
por: Gamper, Eva M., et al.
Publicado: (2021) -
Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial
por: Takumoto, Yuki, et al.
Publicado: (2022) -
Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)